Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability |
| |
Authors: | Helen Swede Thomas E. Rohan Herbert Yu Joseph C. Anderson Richard G. Stevens Jane Brokaw Joel Levine Bruce M. Brenner Carl D. Malchoff Valerie B. Duffy Devon C. Pleau Daniel W. Rosenberg |
| |
Affiliation: | 1. Colon Cancer Prevention Program, Neag Comprehensive Cancer Center, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06030-6325, USA 2. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, 10461, USA 3. Department of Epidemiology and Public Health, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA 4. Global Pharmacovigilance and Epidemiology, Bristol-Myers Squibb, Wallingford, CT, 06492, USA 5. Division of Endocrinology and Metabolism, University of Connecticut Health Center, Farmington, CT, 06030, USA 6. Department of Allied Health Sciences, University of Connecticut, Storrs, CT, 06269, USA
|
| |
Abstract: | Background Dysregulation of the insulin-like growth factor (IGF) system, a common consequence of adiposity-induced insulin resistance, may be a key underlying mechanism linking excess body weight with colon cancer. Evidence has been derived from studies of cancer and polyps. Supporting data about aberrant crypt foci (ACF), putative pre-polyp changes, have been generated only from animal studies to date. Methods We randomly selected 26 patients with sex-specific elevated waist-hip-ratio (WHR) and 26 with normal values from a series of 150 patients seeking routine colonoscopy at the University of Connecticut Health Center. Cross-sectional analyses were performed of ACF number (<5, ≥5) in relation to total IGF1, IGF-binding protein-3 (IGFBP3), insulin, body mass index (BMI), WHR and waist circumference (WC). Visualized ACF in the 20 cm of the distal colon were counted using advanced endoscopic imaging. Results Patients with ≥5 ACF had higher BMI, WHR, and WC compared with patients with >5 ACF (p = 0.04, p = 0.03, and p = 0.01, respectively). IGFBP3 was reduced (p = 0.02) and IGF1:IGFBP3 molar ratio was greater (p = 0.03) in patients with ≥5 ACF. We did not observe significant associations between ACF number and insulin or total IGF1. Conclusions Our study provides the first report in humans of a possible association of ACF prevalence and IGF1 bioavailability as characterized by IGF1:IGFBP3 molar ratio and IGFBP3 level. More research is needed to determine whether this relationship is varied by ACF features (e.g., size, dysplasia, molecular changes), synchronous cancer and polyps, and is modified by colon cancer risk factors. |
| |
Keywords: | Aberrant crypt foci Obesity Adiposity Colon cancer IGF1 IGFBP3 Insulin resistance Metabolic syndrome |
本文献已被 SpringerLink 等数据库收录! |
|